Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus

Curr Rheumatol Rep. 2007 May;9(2):101-8. doi: 10.1007/s11926-007-0003-4.

Abstract

Neonatal lupus syndrome is a model of passively acquired autoimmunity in which the pregnant woman's serum contains specific antibodies to 52 or 60 kd SSA/Ro and/or 48 kd SSB/La, which cross the placenta and are associated with the development of congenital heart block in the fetus and/or a transient rash or various liver and blood cell abnormalities in the newborn. To date, congenital heart block is a permanent condition that entails significant morbidity and mortality, with nearly all affected infants requiring pacemakers and with an 80% cumulative probability of survival at 3 years of age. An intensive search is on for the specific etiopathophysiology and for new clinical tools to approach and treat this disease.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Autoantibodies / blood*
  • Comorbidity
  • Heart Block* / diagnosis
  • Heart Block* / drug therapy
  • Heart Block* / etiology
  • Heart Block* / mortality
  • Heart Defects, Congenital* / diagnosis
  • Heart Defects, Congenital* / drug therapy
  • Heart Defects, Congenital* / etiology
  • Heart Defects, Congenital* / mortality
  • Humans
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical
  • Lupus Erythematosus, Systemic* / complications
  • Lupus Erythematosus, Systemic* / diagnosis
  • Lupus Erythematosus, Systemic* / diet therapy
  • Lupus Erythematosus, Systemic* / mortality
  • Survival Rate
  • United States / epidemiology

Substances

  • Autoantibodies